Stock Taper
SCREENER COMPARE ANY 2 STOCKS
PRME
PRIME MEDICINE, INC.
NASDAQ
$3.61
▼ DOWN 0.82% (-0.03)

KEY STATISTICS

Market Cap$652.03 M
52w High$6.94
52w Low$2.67
Dividend Yield7.89%
FrequencyQuarterly
P/E-3.41
Volume2.69M
Shares Out.180.62M

COMPANY

LEADERSHIP

Allan Reine
CHIEF EXECUTIVE
Allan Reine

COMPENSATION 2026

Salary$606,212
Stock Awards$0
Incentive Plan Pay$402,000
All Other Comp.$57,177
Total$3,894,187

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 20, 2022
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
146

PRICE TARGET

Target High$9.00
Target Low$6.00
Target Median$7.50
Target Consensus$7.50

UPCOMING EARNINGS

DateNov 6, 2026
DayFriday
Rev. Est.$1.32M
NOV
6
FRI

PRICE

$3.61 ▼ DOWN 0.82% (−$0.03)
$3.52$3.60$3.689:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM3.61

About Prime Medicine, Inc.

https://www.primemedicine.com ↗

Prime Medicine, Inc. is a Cambridge-based biotech company founded in 2019 that develops gene editing therapies using Prime Editors, combining Cas proteins and reverse transcriptase enzymes with pegRNA to target and correct specific DNA sequences.

INDUSTRY

Biotechnology

A PRODUCT PRIME MEDICINE, INC. IS KNOWN FOR

PM359
PM359

PM359 is an investigational autologous stem cell therapy using Prime Editing to treat CGD, with FDA clearance for clinical trials, representing Prime Medicine's most advanced candidate.

COMPETITORS

COMPETITOR
BEAM COMPARE
CRSP COMPARE
EDIT COMPARE
NTLA COMPARE
VRTX COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Reportable Segment$1.23M $838K ▼$856K ▲$1.15M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
107
LISTED HERE
19
RANKED BY POSITION SIZE
ARKG
1.36% · 8.0M
XBI
0.17% · 5.6M
VTS.AX
0.00% · 3.1M
IWM
0.01% · 2.5M
SCHA
0.01% · 516.2K
LABU
0.12% · 202.6K
NXTE
0.95% · 139.2K
DFAS
0.00% · 122.6K
BBC
0.79% · 113.0K
XRSG.L
0.01% · 79.5K
PRFZ
0.01% · 78.6K
GNOM
0.27% · 67.7K
FHLC
0.01% · 50.1K
GINN
0.05% · 26.1K
ESSC
0.09% · 11.6K
BIB
0.02% · 6.5K
VETS
0.04% · 3.3K
USUE.DE
0.00% · 493
RESM
0.01% · 186

INSTITUTIONAL OWNERSHIP

SHARES OWNED
45.65%
HOLDERS
249
TOP 12 OF 249 · RANKED BY POSITION SIZE
Alphabet Inc.
16.6M sh · $61.12M
Blackrock, Inc.
9.6M sh · $35.43M
T. Rowe Price Investment Management, Inc.
9.2M sh · $51.06M
Ark Investment Management LLC
8.3M sh · $30.81M
State Street Corp
7.6M sh · $27.96M
Vanguard Group Inc
6.5M sh · $22.44M
Blackrock Inc.
5.1M sh · $26.27M
Farallon Capital Management LLC
4.8M sh · $26.32M
Balyasny Asset Management L.P.
4.1M sh · $14.35M
Nikko Asset Management Americas, Inc.
3.6M sh · $20.04M
Sumitomo Mitsui Trust Holdings, Inc.
3.6M sh · $20.11M
Goldman Sachs Group Inc
3.4M sh · $12.66M

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
DIRECTOR
Chung Wendy
Purchase · 75.0K shares
2026-06-05
★
DIRECTOR
Cahill Thomas
Purchase · 75.0K shares
2026-06-05
★
DIRECTOR
Schenkein David P
Purchase · 75.0K shares
2026-06-05
★
DIRECTOR
Marrazzo Jeffrey D
Purchase · 75.0K shares
2026-06-05

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
OUTPERFORM 1
NEUTRAL 1
4 GRADES IN THE LAST 12 MONTHS
Chardan Capital BUY BMO Capital OUTPERFORM HC Wainwright & Co. BUY Citigroup NEUTRAL

SECTORS PEERS

PEERPRICE
VIR$10.83COMPARE
SEPN$38.91COMPARE
BCAX$23.43COMPARE
TYRA$24.94COMPARE
REPL$15.50COMPARE
KURA$12.66COMPARE
MRVI$7.68COMPARE
RZLT$4.62COMPARE